CognitionPhase 4NCT03781557
Effects of Omega-3 Fatty Acids Supplement in Cognition of Young Healthy Adults and in Their Reaction Time of Computerized Test After 3 Months of Taking High-concentrated DHA and EPA Fish Softgels
A Phase 4 study testing Docosahexaenoic acid, Eicosapentaenoic acid and Olive oil in people with Cognition and Brain, run by Sulaiman AlRajhi Colleges.
Trial summary
In this trial, the investigators are going to investigate the improvement of cognitive brain domains after ingestion of omega 3 products that have high concentrations of DHA, Docosahexaenoic acid, and EPA, Eicosapentaenoic acid, in comparison to control group young healthy adults. Read more about this study
- Who is it for?
- Ages 18 to 25 yearsHealthy volunteers can take part
- Conditions the study is for
- Cognition, Brain, Neuroscience
- What is being tested?
- Docosahexaenoic acid, Eicosapentaenoic acid and Olive oil
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 60 participants
- Where
- No sites listed yet
- Study dates
- 1 Jan 2019to 29 May 2019
- Phase
- Phase 4
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 25 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Healthy
- Young Adult (18-25)
Who cannot join
- Diet rich in fish oil: subjects should not use a diet rich in omega 3 poly-unsaturated fatty acids, that is defined as more than one portion a week or more than 4 portions a month of the following food items
- Salmon Sardines • Flaxseed oil or whole flaxseed Illicit drug use
- Medications of mental illnesses or that affect brain functions
- Fish Allergy
Trial locations and contacts
No sites are listed yet.
About this study
Official title: Effect of Omega-3 in Cognition of Young Healthy Adult
In this trial, the investigators are going to investigate the improvement of cognitive brain domains after ingestion of omega 3 products that have high concentrations of DHA, Docosahexaenoic acid, and EPA, Eicosapentaenoic acid, in comparison to control group young healthy adults. The study will assess the improvement by computerized testing by their reaction time before and after the intervention. The researchers will follow the scientific and ethical regulations prevent any harmful effect on recruited subjects.
Read the detailed description
Research Question :
Research question: Will daily consumption of omega-3 fish oil improve brain cognitive domains?
Study Methodology Research Design:
A placebo-controlled, double-blinded, 3-armed randomized controlled trial.
Population and Sample :
Our target population will be young, healthy adults, educated academic students which are the students of Sulaiman Alrajhi Colleges in Kingdom of Saudi Arabia.
Regarding the sample size, the investigators will put into consideration the confidence level of 95%. Also, the investigators will take into account the size of our population which is the number of students in Sulaiman Al-Rajhi Colleges. In addition to that, the investigators will consider the margin of error to be around 10%. Taking these variables together will give us an estimated sample size of about 66 students which the investigators will reduce to 60 due to financial limitations.
Sampling strategy:
The investigators will recruit the participants from the students of Suliman Alrajhi Colleges by announcing through the emails and by spreading paper announcements in the campus and the housing for volunteering in the research as subjects and the investigators will try to give the participants activity points after coordinating with the students' affairs department. If more than 60 students volunteered for the trial, then the investigators will choose 60 of them based on the exclusion and inclusion criteria and by random sequence generation.
Plan of subjects' recruitment:
The investigators will recruit our subjects from the students of Suliman Al-Rajhi Colleges, both males and females sectors. The sample size will be 60 students in 3 arms (20 control, 20 high doses of Docosahexaenoic acid, DHA, and 20 high doses of Eicosapentaenoic acid, EPA,). The investigators will take the baseline characteristics and do the preliminary cognitive testing using Psytest, (TAP 2.3.1) software. Recruiting the subjects will be according to the exclusion and inclusion criteria mentioned below. After collecting the sample, the investigators will enroll the subjects in the study 6 students a day. So that the investigators will do the preliminary testing and take the baseline characteristics for 6 students at day 1 and then the day after the same group will start taking the intervention (either high dose DHA or high dose EPA or placebo) and another 6 students will be enrolled and so on. Hence day 10 will be the last day of enrollment and the process of enrollment will take 10 days. So, the investigators are going to have ten groups of subjects allocated randomly to the three arms of the study. After 90 days from the date of the enrollment, each group will be assessed, and the post-intervention testing will be carried out. The investigators will take the informed consent from all participant after explaining everything about the study and the potential side effects of supplements, in addition, to take their written agreement after explaining all their inquiries about the study.
Plan of data collectors' recruitment:
The investigators need the data collectors to help to keep an updated information on the subjects and assisting in the process of distributing the pills and their regular intake and also they will ensure quick communication. The investigators will need ten data collectors so that each data collector will supervise a group of six subjects, and these six students will be randomly assigned as mentioned before.
Randomization:
The investigators will do Block randomization in order to have equal numbers in the three arms of the study. Computer-generated random allocation sequences will be used, www.randomizer.org, and when carried out the randomization will help us avoiding selection bias so that no systematic differences exist. Then, the investigators will distribute the subjects in the three arms of the study randomly.
Blinding:
The investigators will make sure that the soft-gels of the DHA group, EPA group, and placebo group will look the same and taste the same so that blinding is not broken and allocation concealment is ensured. The investigators will also try to make the study double blinded.
Supplements and placebo groups:
The investigators will divide randomly the participants to three main groups who will take two softgels of different supplements which are:
- EPA-high-concentrated fish oil softgels that will provide 1374 mg of EPA and 500 DHA fatty acids per day out of 2500 mg total fat. The chosen product for this concentration is : , Sports Research, Omega-3 Fish Oil, Triple Strength, 1250 mg, 180 Softgels,
- DHA-high-concentrated fish oil softgels that will provide 1400 mg of DHA fatty acids per day out of 2000 mg of total fat. The chosen product for this concentration is : , DHA 700 Fish Oil,
- Olive oil softgels as a placebo that will be totally 2500 mg of fat The chosen product for this is :
- Healthy Origin, Extra Virgin Olive Oil softgels,
The softgels will be taken every day by oral administration for 60 days and the participants will be instructed and followed by the investigators to take them after the meal and roughly in the same time to unify any possible factor during taking it. The investigators suggest taking it after launch meal immediately. The supplements will be stored in a healthy, cold, and safe environment to guarantee the bioavailability of the products.
The investigators will try to ensure that all supplements capsules have the same out-shape characteristics like color, shape, and size to enhance the double blinding that the investigators put in our research criteria. In addition, the investigators will bring uniformed containers to store the soft-gels and distribute the soft-gels among them to maintain blinding for researchers. That will be the same during distributing the capsules to the participants and it will be in a good-saving uniformed container.
Safety:
Many supplements of omega-3 are US FDA and Saudi FDA approved and can be found in the approved drugs list of each organization). According to the European Food Safety Authority in 2012 , long-term consumption of EPA and DHA supplements at combined doses of up to about 5 g/day, or EPA alone up to 1.8 g/day appear to be safe for the adult population and does not increase the risk of spontaneous bleeding episodes, or affect glucose homeostasis, immune function or lipid peroxidation.
Data collection and communication:
The investigators will distribute a limited amount of softgels every week and check for taking softgels.
Criteria for stopping follow-up and intervention in the subject:
Allergic reaction or exacerbated side effects that cannot be afforded Failure to daily follow-up and compliance to take the supplementation
Medication use :
Autoimmune disease Significant changes in lifestyle throughout the supplementation interval Including a 6.8 kg weight loss
Analysis:
The investigators will analyze the data using the SPSS software program. Descriptive analysis and statistical Drop-outs from the study will be excluded from the analysis, so the analysis type will be, per protocol analysis.
- Conditions
- Cognition, Brain, Neuroscience
- Being tested
- Docosahexaenoic acid, Eicosapentaenoic acid, Olive oil
- Keywords
- Omega-3, DHA fatty acids, EPA fatty acids, Cognition, Brain, Healthy Adult, Fish Oil, Human
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Docosahexaenoic acidDietary supplement
Also called MadreLabs, DHA 700 Fish Oil
High-concentrated DHA
Eicosapentaenoic acidDietary supplement
Also called Sports Research, Omega-3 Fish Oil, Triple Strength
High-concentrated EPA
Olive oilDietary supplement
Olive Oil softgels
| Study group | Role | What they receive |
|---|---|---|
| High-concentrated DHA | Experimental | High-concentrated DHA fish oil softgels Receives: Dietary Supplement: Docosahexaenoic acid |
| High-concentrated EPA | Experimental | High-concentrated EPA fish oil softgels Receives: Dietary Supplement: Eicosapentaenoic acid |
| Olive Oil | Placebo comparator | Olive Oil softgels Receives: Dietary Supplement: Olive oil |
What is being measured
The primary outcome is the main question the study is designed to answer.
Attention
it will be measured by Psytest (TAP 2.3.1) computerised test to assess the reaction time related to it by milliseconds
Measured: 5 minutes
Working memory
Working memory can be looked at as a system that keeps the information essential for solving difficult dilemmas and processing multi-level tasks or aspects of a situation in order to bring about a final impression.
it will be measured by Psytest (TAP 2.3.1) computerised test to assess the reaction time related to it by milliseconds.
Measured: 5 minutes
Sustained attention
it will be measured by Psytest (TAP 2.3.1) computerised test to assess the reaction time related to it by milliseconds.
Measured: 15 minutes
stimulus-reaction incompatibility (Simon effect)
Incompatibility occurs in a conflict situation in which divergent stimulus information has to be processed in parallel, thus triggering different reaction tendencies. The Simon and the Stroop effects (in the Colour-Word Interference Test) are classic examples of this effect.
The present procedure tests the interference tendency in terms of stimulus-reaction incompatibility (Simon effect) . For this test, arrows that are directed to the left or the right are presented on the left or the right of a fixation point. Depending on the direction of the arrow, the test person should respond with the right or left hand irrespective of the side on which the arrow is presented.
Measured: 3 minutes
Go/ No go
this test will measure the specific ability of the subject to suppress an inappropriate response and to react only on the appearance of some stimuli and not in the presence of others, which requires significant central intervention.
it will be measured by Psytest (TAP 2.3.1) computerised test to assess the reaction time related to it by milliseconds.
Measured: 5 minutes
Divided attention
In this test, an auditory and a visual task must be taken simultaneously, to measure the subject's ability to carry out more than one task at the same time.
it will be measured by Psytest (TAP 2.3.1) computerised test to assess the reaction time related to it by milliseconds.
Measured: 10 minutes
Alertness
In this test, we will measure the reaction time. Simple reaction time measurements will be done, in which a diamond appears on the screen at random intervals and to which the subject should respond as quickly as possible by pressing a button.
it will be measured by Psytest (TAP 2.3.1) computerised test to assess the reaction time related to it by milliseconds.
Measured: 5 minutes
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Dec 2018
- Study start1 Jan 2019 (estimated)
- Primary completion1 Apr 2019 (estimated)
- Study completion29 May 2019 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for CognitionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 4
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 60 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Sulaiman AlRajhi Colleges
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03781557
- Sponsor's protocol ID
- SulimanAC-Omega-3
- Status last verified
- Dec 2018
- First submitted
- 12 Dec 2018
- Last updated
- 20 Dec 2018
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 20 Dec 2018. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effect of Omega-3 in Cognition of Young Healthy Adult
- ClinicalTrials.gov ID
- NCT03781557
- Acronym / sponsor ID
- SulimanAC-Omega-3
- Conditions
- Cognition, Brain, Neuroscience
- Keywords
- Omega-3, DHA fatty acids, EPA fatty acids, Cognition, Brain, Healthy Adult, Fish Oil, Human
- Phase
- Phase 4
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 60 participants (estimated)
- Lead sponsor
- Sulaiman AlRajhi CollegesUniversity, hospital or other
- Study start
- 1 Jan 2019 (estimated)
- Primary completion
- 1 Apr 2019 (estimated)
- Study completion
- 29 May 2019 (estimated)
- First posted
- 20 Dec 2018 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
In this trial, the investigators are going to investigate the improvement of cognitive brain domains after ingestion of omega 3 products that have high concentrations of DHA, Docosahexaenoic acid, and EPA, Eicosapentaenoic acid, in comparison to control group young healthy adults. The study will assess the improvement by computerized testing by their reaction time before and after the intervention. The researchers will follow the scientific and ethical regulations prevent any harmful effect on recruited subjects.
Detailed description
Research Question :
Research question: Will daily consumption of omega-3 fish oil improve brain cognitive domains?
Study Methodology Research Design:
A placebo-controlled, double-blinded, 3-armed randomized controlled trial.
Population and Sample :
Our target population will be young, healthy adults, educated academic students which are the students of Sulaiman Alrajhi Colleges in Kingdom of Saudi Arabia.
Regarding the sample size, the investigators will put into consideration the confidence level of 95%. Also, the investigators will take into account the size of our population which is the number of students in Sulaiman Al-Rajhi Colleges. In addition to that, the investigators will consider the margin of error to be around 10%. Taking these variables together will give us an estimated sample size of about 66 students which the investigators will reduce to 60 due to financial limitations.
Sampling strategy:
The investigators will recruit the participants from the students of Suliman Alrajhi Colleges by announcing through the emails and by spreading paper announcements in the campus and the housing for volunteering in the research as subjects and the investigators will try to give the participants activity points after coordinating with the students' affairs department. If more than 60 students volunteered for the trial, then the investigators will choose 60 of them based on the exclusion and inclusion criteria and by random sequence generation.
Plan of subjects' recruitment:
The investigators will recruit our subjects from the students of Suliman Al-Rajhi Colleges, both males and females sectors. The sample size will be 60 students in 3 arms (20 control, 20 high doses of Docosahexaenoic acid, DHA, and 20 high doses of Eicosapentaenoic acid, EPA,). The investigators will take the baseline characteristics and do the preliminary cognitive testing using Psytest, (TAP 2.3.1) software. Recruiting the subjects will be according to the exclusion and inclusion criteria mentioned below. After collecting the sample, the investigators will enroll the subjects in the study 6 students a day. So that the investigators will do the preliminary testing and take the baseline characteristics for 6 students at day 1 and then the day after the same group will start taking the intervention (either high dose DHA or high dose EPA or placebo) and another 6 students will be enrolled and so on. Hence day 10 will be the last day of enrollment and the process of enrollment will take 10 days. So, the investigators are going to have ten groups of subjects allocated randomly to the three arms of the study. After 90 days from the date of the enrollment, each group will be assessed, and the post-intervention testing will be carried out. The investigators will take the informed consent from all participant after explaining everything about the study and the potential side effects of supplements, in addition, to take their written agreement after explaining all their inquiries about the study.
Plan of data collectors' recruitment:
The investigators need the data collectors to help to keep an updated information on the subjects and assisting in the process of distributing the pills and their regular intake and also they will ensure quick communication. The investigators will need ten data collectors so that each data collector will supervise a group of six subjects, and these six students will be randomly assigned as mentioned before.
Randomization:
The investigators will do Block randomization in order to have equal numbers in the three arms of the study. Computer-generated random allocation sequences will be used, www.randomizer.org, and when carried out the randomization will help us avoiding selection bias so that no systematic differences exist. Then, the investigators will distribute the subjects in the three arms of the study randomly.
Blinding:
The investigators will make sure that the soft-gels of the DHA group, EPA group, and placebo group will look the same and taste the same so that blinding is not broken and allocation concealment is ensured. The investigators will also try to make the study double blinded.
Supplements and placebo groups:
The investigators will divide randomly the participants to three main groups who will take two softgels of different supplements which are:
- EPA-high-concentrated fish oil softgels that will provide 1374 mg of EPA and 500 DHA fatty acids per day out of 2500 mg total fat. The chosen product for this concentration is : , Sports Research, Omega-3 Fish Oil, Triple Strength, 1250 mg, 180 Softgels,
- DHA-high-concentrated fish oil softgels that will provide 1400 mg of DHA fatty acids per day out of 2000 mg of total fat. The chosen product for this concentration is : , DHA 700 Fish Oil,
- Olive oil softgels as a placebo that will be totally 2500 mg of fat The chosen product for this is :
- Healthy Origin, Extra Virgin Olive Oil softgels,
The softgels will be taken every day by oral administration for 60 days and the participants will be instructed and followed by the investigators to take them after the meal and roughly in the same time to unify any possible factor during taking it. The investigators suggest taking it after launch meal immediately. The supplements will be stored in a healthy, cold, and safe environment to guarantee the bioavailability of the products.
The investigators will try to ensure that all supplements capsules have the same out-shape characteristics like color, shape, and size to enhance the double blinding that the investigators put in our research criteria. In addition, the investigators will bring uniformed containers to store the soft-gels and distribute the soft-gels among them to maintain blinding for researchers. That will be the same during distributing the capsules to the participants and it will be in a good-saving uniformed container.
Safety:
Many supplements of omega-3 are US FDA and Saudi FDA approved and can be found in the approved drugs list of each organization). According to the European Food Safety Authority in 2012 , long-term consumption of EPA and DHA supplements at combined doses of up to about 5 g/day, or EPA alone up to 1.8 g/day appear to be safe for the adult population and does not increase the risk of spontaneous bleeding episodes, or affect glucose homeostasis, immune function or lipid peroxidation.
Data collection and communication:
The investigators will distribute a limited amount of softgels every week and check for taking softgels.
Criteria for stopping follow-up and intervention in the subject:
Allergic reaction or exacerbated side effects that cannot be afforded Failure to daily follow-up and compliance to take the supplementation
Medication use :
Autoimmune disease Significant changes in lifestyle throughout the supplementation interval Including a 6.8 kg weight loss
Analysis:
The investigators will analyze the data using the SPSS software program. Descriptive analysis and statistical Drop-outs from the study will be excluded from the analysis, so the analysis type will be, per protocol analysis.
Study design
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| High-concentrated DHA | Experimental | Dietary Supplement: Docosahexaenoic acidHigh-concentrated DHA fish oil softgels |
| High-concentrated EPA | Experimental | Dietary Supplement: Eicosapentaenoic acidHigh-concentrated EPA fish oil softgels |
| Olive Oil | Placebo comparator | Dietary Supplement: Olive oilOlive Oil softgels |
Who may qualify
- Ages
- 18 to 25 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (2 listed)
- Healthy
- Young Adult (18-25)
Key exclusion criteria (4 listed)
- Diet rich in fish oil: subjects should not use a diet rich in omega 3 poly-unsaturated fatty acids, that is defined as more than one portion a week or more than 4 portions a month of the following food items
- Salmon Sardines • Flaxseed oil or whole flaxseed Illicit drug use
- Fish Allergy
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Docosahexaenoic acidAlso: MadreLabs, DHA 700 Fish OilHigh-concentrated DHA | Dietary supplement | High-concentrated DHA |
| Eicosapentaenoic acidAlso: Sports Research, Omega-3 Fish Oil, Triple StrengthHigh-concentrated EPA | Dietary supplement | High-concentrated EPA |
| Olive oilOlive Oil softgels | Dietary supplement | Olive Oil |
Primary outcome
Attention
Time frame: 5 minutes
it will be measured by Psytest (TAP 2.3.1) computerised test to assess the reaction time related to it by milliseconds
Working memory
Time frame: 5 minutes
Working memory can be looked at as a system that keeps the information essential for solving difficult dilemmas and processing multi-level tasks or aspects of a situation in order to bring about a final impression. it will be measured by Psytest (TAP 2.3.1) computerised test to assess the reaction time related to it by milliseconds.
Sustained attention
Time frame: 15 minutes
it will be measured by Psytest (TAP 2.3.1) computerised test to assess the reaction time related to it by milliseconds.
stimulus-reaction incompatibility (Simon effect)
Time frame: 3 minutes
Incompatibility occurs in a conflict situation in which divergent stimulus information has to be processed in parallel, thus triggering different reaction tendencies. The Simon and the Stroop effects (in the Colour-Word Interference Test) are classic examples of this effect. The present procedure tests the interference tendency in terms of stimulus-reaction incompatibility (Simon effect) . For this test, arrows that are directed to the left or the right are presented on the left or the right of a fixation point. Depending on the direction of the arrow, the test person should respond with the right or left hand irrespective of the side on which the arrow is presented.
Go/ No go
Time frame: 5 minutes
this test will measure the specific ability of the subject to suppress an inappropriate response and to react only on the appearance of some stimuli and not in the presence of others, which requires significant central intervention. it will be measured by Psytest (TAP 2.3.1) computerised test to assess the reaction time related to it by milliseconds.
Divided attention
Time frame: 10 minutes
In this test, an auditory and a visual task must be taken simultaneously, to measure the subject's ability to carry out more than one task at the same time. it will be measured by Psytest (TAP 2.3.1) computerised test to assess the reaction time related to it by milliseconds.
Alertness
Time frame: 5 minutes
In this test, we will measure the reaction time. Simple reaction time measurements will be done, in which a diamond appears on the screen at random intervals and to which the subject should respond as quickly as possible by pressing a button. it will be measured by Psytest (TAP 2.3.1) computerised test to assess the reaction time related to it by milliseconds.
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 20 Dec 2018.
Related trials for Cognition
Recruiting
Metabolic Health, Bones and Nuts During Weight Loss in Adults
Weight Loss, Bone Density
Not yet recruitingPhase 2
Lisdexamfetamine For the Treatment of Conduct Disorder in Children
Conduct Disorder
RecruitingPhase 4
Lidocaine Infiltration and Neuroimmunomodulation in Head and Neck Cancer Surgery
Head and Neck Cancer (H&N)
Recruiting
HEARS-NPS: Addressing Hearing Loss as a Common Unmet Contributor of Neuropsychiatric Symptoms
Alzheimer Disease, Dementia
RecruitingObservational study
Locus Coeruleus and CCHS (Congenital Central Hypoventilation Syndrome)
Ondine Syndrome (Congenital Central Hypoventilation Syndrome)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Questions about this trial
What is this clinical trial studying?
A Phase 4 study testing Docosahexaenoic acid, Eicosapentaenoic acid and Olive oil in people with Cognition and Brain, run by Sulaiman AlRajhi Colleges.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 20 Dec 2018. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact WESAM ALKASSAS, MBBS (+966538975400, 13110021@srcolleges.org), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Attention (time frame: 5 minutes). The study lists 7 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Dec 2018.